✦ LIBER ✦

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

✍ Scribed by Christophe Le Tourneau; Sandrine Faivre; Valérie Laurence; Catherine Delbaldo; Karina Vera; Veronique Girre; Judy Chiao; Sian Armour; Sheelagh Frame; Simon R. Green; Athos Gianella-Borradori; Veronique Diéras; Eric Raymond

Book ID: 116430513
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 378 KB
Volume: 46
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2010.08.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of the selective oral cy

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

✍ Benson, C; White, J; Bono, J De; O'Donnell, A; Raynaud, F; Cruickshank, C; McGra 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

Preliminary results of an ongoing phase

Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 140 KB

281 POSTER A phase I study of R547, a no

281 POSTER A phase I study of R547, a novel cyclin dependent kinase inhibitor, in patients (pts) with advanced cancer: preliminary results

✍ D.R. Camidge; S.G. Eckhardt; A. Tan; G. Frenette; S. Diab; W. Depinto; J.F. Grip 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Phase I Study of RGB-286638, A Novel, Mu

Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors

✍ van der Biessen, D. A. J.; Burger, H.; de Bruijn, P.; Lamers, C. H. J.; Naus, N. 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 589 KB

Effect of aprepitant on the pharmacokine

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies

✍ Zhang, Da; Mita, Monica; Shapiro, Geoffrey I.; Poon, Jennifer; Small, Karen; Tzo 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 322 KB

A first-in-human, phase 1, dose-escalati

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

✍ Nemunaitis, John J; Small, Karen A; Kirschmeier, Paul; Zhang, Da; Zhu, Yali; Jou 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 353 KB